A Phase 4 interventional study of Methotrexate (stable dose) and Tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Terminated at 67 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-14.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 17th largest by enrollment, is one of 11 that started in 2012, is one of 38 in phase 4, and was the 66th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 11 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 427 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 31st largest by enrollment of the 141 interventional ones that give a count, is one of 37 that started in 2012, is one of 28 in phase 4, and was the 142nd registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized, placebo-controlled, double-blind study will compare the safety and efficacy of tapering methotrexate (MTX) versus maintaining MTX dosage in patients with severe active rheumatoid arthritis and an inadequate response to disease-modifying antirheumatic drugs (DMARDs) initiated on treatment with tocilizumab. Participants will receive tocilizumab 8 mg/kg intravenously every 4 weeks and MTX orally weekly throughout the study. At Week 24, participants achieving a good/moderate EULAR response will be randomized receiving the MTX Tapering arm or MTX Maintenance arm. Up to Week 56 participants will receive either tapering or stable dose MTX in combination with tocilizumab. From Week 56 to Week 72 participants will receive tocilizumab monotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
At Week 0 participants will start open-label tocilizumab and open-label MTX for 24 weeks. At Week 24, participants achieving a good/moderate European League Against Rheumatism (EULAR) disease response will be randomized to the MTX Tapering group or MTX Maintenance group. In this arm participants will receive a double-blind MTX dose according to the MTX tapering scheme between Week 24 and Week 56. Participants will also continue to receive open-label tocilizumab between Week 24 and Week 56. From Week 56 to Week 72 participants will receive tocilizumab monotherapy.
Drug: Tocilizumab · Drug: Methotrexate (tapering dose)
At Week 0 participants will start open-label tocilizumab and open-label MTX for 24 weeks. At Week 24, participants achieving a good/moderate European League Against Rheumatism (EULAR) disease response will be randomized to the MTX Tapering group or MTX Maintenance group. In this arm participants will continue to be administered a stable dose of MTX in a double-blind fashion between Week 24 and Week 56. Participants will also continue to receive open-label tocilizumab between Week 24 and Week 56. From Week 56 to Week 72 participants will receive tocilizumab monotherapy.
Drug: Methotrexate (stable dose) · Drug: Tocilizumab
Methotrexate (MTX) was administered weekly according to the subject's pre-study MTX dose
8 mg/kg intravenously every 4 weeks for 72 weeks
Also known as: RoActemra/Actemra
Tapering doses of methotrexate (MTX) were administered weekly from Week 24 to Week 56. Tapering doses depended on dose administered to the subject during the open label period. First tapering occurred at randomization (Week 24), second tapering at Week 32, third tapering at Week 40 and final tapering at Week 48.
Percentage of Participants Maintaining Previous Disease Activity (European League Against Rheumatism [EULAR] Response) From Week 24 (Time of Randomization) to Week 60
Response was determined using EULAR criteria based upon (Disease Activity Score In 28 Joints) DAS28 absolute scores at the assessment visit and the DAS28 reduction from the reference visit. Participants with a score lesser than or equal to (\<=) 3.2 and reduction of greater than (\>) 1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score \<=5.1 with reduction of \>0.6 to \<=1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to \<=1.2 points, or any score with reduction \<=0.6 points, were assessed as non-responders with response recorded as 'none.'
Time frame: From randomization to Week 60
Change From Baseline in Disease Activity Score In 28 Joints (DAS28) Score at Week 60
The DAS28 defined as a combined index for measuring disease activity in rheumatoid arthritis (RA). The index included swollen (range 0-28) and tender joint counts (TJC) (range 0-28), acute phase response Erythrocyte Sedimentation Rate (ESR), and general health status (range 1-100). The index was calculated using the following formula: The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x patient global assessment of disease activity\]. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.
Time frame: Randomization (Week 24), Week 60
Change From Baseline in Disease Activity Score In 28 Joints (DAS28) Score at Week 72
The DAS28 defined as a combined index for measuring disease activity in rheumatoid arthritis (RA). The index included swollen (range 0-28) and tender joint counts (TJC) (range 0-28), acute phase response Erythrocyte Sedimentation Rate (ESR), and general health status (range 1-100). The index was calculated using the following formula: The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x patient global assessment of disease activity\]. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.
Time frame: Randomization (Week 24), Week 72
Percentage of Participants Who Achieve Score of <=1 in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 60 and 72
Percentage of participants who achieve score of =1 in TJC and SJC at week 60 and 72 were reported. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28.
Time frame: Week 60, 72
Percentage of Participants Who Achieve a Disease Activity Score In 28 Joints (DAS28) <= 3.2
The DAS28 index was calculated using the following formula: The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x patient global assessment of disease activity\]. Participants who achieve score \<=3.2 at weeks 60 and 72 were reported.
Time frame: Week 60, 72
Percentage of Participants Who Achieve DAS28 Remission (DAS28 < 2.6)
The DAS28 index was calculated using the following formula: The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x patient global assessment of disease activity\]. Participants who achieve DAS28 remission score \<2.6 at weeks 60 and 72 were reported.
Time frame: Week 60, 72
Percentage of Participants Who Achieve Change in Disease Activity Score (cDAS) >=1.2
The DAS28 index was calculated using the following formula: The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x patient global assessment of disease activity\]. Participants who achieve cDAS28 \>=1.2 score at weeks 60 and 72 were reported.
Time frame: Week 60, 72
Percentage of Participants Who Achieve Clinical Disease Activity Index (CDAI) Remission (CDAI < 2.8) at Week 60 and 72
Clinical Disease Activity Index (CDAI) was an index for measuring disease activity in RA. The index was calculated using the following formula: CDAI: SJC28 + TJC28 + patient global assessment of disease (PGA) 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 'no disease activity' to 'maximum disease activity.' CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity.
Time frame: Randomization (Week 24), Week 60, 72
Percentage of Participants Who Achieve Simplified Disease Activity Index (SDAI) Remission (SDAI < 3.3) at Week 60 and 72
Simplified Disease Activity Index (SDAI) was an index for measuring disease activity in RA. The index was calculated using the following formula: CDAI: SJC28 + TJC28 + PGA (10 cm VAS) + PhGA (10 cm VAS + C-Reactive Protein (CRP). VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity. Scores ranged from 0 to 86, with higher scores also indicating increased disease activity.
Time frame: Randomization (Week 24), Week 60, 72
Percentage of Participants With Improvement in Physical Function Using Health Assessment Questionnaire [HAQ] at Week 60 and 72
The HAQ-disability index (DI) evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores and 20 questions. Each category contains multiple questions, which were answered using a 4-point scale from 0 to 3. The overall index score was an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. Improvement was defined as a decrease from Week 24 to Week 60 and 72. Reported is the percentage of participants with an improvement in HAQ-DI score.
Time frame: Randomization (Week 24), Week 60, 72
Percentage of Participants With Improvement in Physical Function Using Functional Assessment of Chronic Illness Therapy - Fatigue [FACIT-F] at Week 60 and 72
The FACIT-fatigue assessment was a 13-item questionnaire with participants scoring each item on a 5-point scale (not at all; a little bit; somewhat; quite a bit and very much). The total score ranges from 0 to 65 and higher scores indicate more fatigue. Improvement was defined as a decrease from Week 24 to Week 60 and 72. Reported is the percentage of subjects with an improvement in total FACIT score.
Time frame: Randomization (Week 24), Week 60, 72
Percentage of Participants With Improvement in Physical Function Using 12-item Short Form Health Survey [SF-12]) at Week 60 and 72
Quality of life questionnaire (SF-12) scores were computed using the scores of 12 questions and ranged from 0 to 100, where a 0 score indicated the lowest level of health measured by the scales and 100 indicated the highest level of health. Improvement was defined as a decrease from Week 24 to Week 60 and 72. Reported is the percentage of subjects with an improvement in SF-12 score.
Time frame: Randomization (Week 24), Week 60, 72
Percentage of Participants With Anemia
Time frame: Week 0 up to Week 72
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE was any adverse event that can be fatal, life threatening, requires long or prolong hospitalization, results in persistent or significant disability/incapacity, congenital anomaly or significant medical event in the investigator's judgment.
Time frame: Week 0 up to Week 72
Percentage of Participants Able to Discontinue Methotrexate
Time frame: Week 0 up to Week 60
Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP)
The WPAI-SHP questionnaire assesses work productivity and activity impairment. It is a patient-reported assessment regarding hours missed and hours worked at employment and degree to which a specified health problem affected work productivity and regular activities. It consists of 6 questions to assess the impact of a specific health problem on work productivity and on regular daily activities.
Time frame: Randomization (Week 24), Week 60, 72
Hours Actually Worked and Work Hours Missed Assessed Using the WPAI-SHP
The WPAI-SHP questionnaire assesses work productivity and activity impairment. It is a patient-reported assessment regarding hours missed and hours worked at employment and degree to which a specified health problem affected work productivity and regular activities. It consists of 6 questions to assess the impact of a specific health problem on work productivity and on regular daily activities. Reported here are hours actually worked, work hours missed due to rheumatoid arthritis (RA), work hours missed due to other reasons and the change from Week 24 for each of these parameters reported at Week 60 and Week 72.
Time frame: Randomization (Week 24), Week 60, Week 72
Change in Productivity and Regular Daily Activities Affected by Rheumatoid Arthritis Assessed Using the WPAI-SHP
The WPAI-SHP questionnaire assesses work productivity and activity impairment. It is a patient-reported assessment regarding hours missed and hours worked at employment and degree to which a specified health problem affected work productivity and regular activities. It consists of 6 questions to assess the impact of a specific health problem on work productivity and on regular daily activities. Assessments were made using a visual analogue scale ranging from 0 to 10 where 0 = minimum impact and 10 = maximum impact.
Time frame: Randomization (Week 24), Week 60, 72
| Milestone | Initial Phase | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|---|
| Started | 427 | 0 | 0 |
| Completed | 351 | 0 | 0 |
| Not completed | 76 | 0 | 0 |
| Withdrew: Adverse event | 44 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 5 | 0 | 0 |
| Withdrew: Investigator decision | 3 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Administrative/other | 1 | 0 | 0 |
| Withdrew: Sponsor termination | 16 | 0 | 0 |
| Withdrew: Did not meet eular criteria | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
| Milestone | Initial Phase | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|---|
| Started | 0 | 136 | 136 |
| Completed | 0 | 95 | 86 |
| Not completed | 0 | 41 | 50 |
| Withdrew: Refused treatment | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 16 | 18 |
| Withdrew: Protocol violation | 0 | 2 | 3 |
| Withdrew: Withdrawal by subject | 0 | 1 | 3 |
| Withdrew: Investigator's decision | 0 | 1 | 2 |
| Withdrew: Sponsor termination | 0 | 14 | 17 |
| Withdrew: Administrative/other | 0 | 7 | 6 |
Response was determined using EULAR criteria based upon (Disease Activity Score In 28 Joints) DAS28 absolute scores at the assessment visit and the DAS28 reduction from the reference visit. Participants with a score lesser than or equal to (\<=) 3.2 and reduction of greater than (\>) 1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score \<=5.1 with reduction of \>0.6 to \<=1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to \<=1.2 points, or any score with reduction \<=0.6 points, were assessed as non-responders with response recorded as 'none.'
| percentage of participants | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|
| Percentage of Participants Maintaining Previous Disease Activity (European League Against Rheumatism [EULAR] Response) From Week 24 (Time of Randomization) to Week 60 | 76.5 | 65.4 |
The DAS28 defined as a combined index for measuring disease activity in rheumatoid arthritis (RA). The index included swollen (range 0-28) and tender joint counts (TJC) (range 0-28), acute phase response Erythrocyte Sedimentation Rate (ESR), and general health status (range 1-100). The index was calculated using the following formula: The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x patient global assessment of disease activity\]. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.
| units on a scale | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|
| Baseline (n= 135, 136) | 2.572 ± 1.3218 | 2.573 ± 1.3017 |
| Change at Week 60 (n= 134, 135) | -0.179 ± 1.1702 | -0.233 ± 1.5156 |
The DAS28 defined as a combined index for measuring disease activity in rheumatoid arthritis (RA). The index included swollen (range 0-28) and tender joint counts (TJC) (range 0-28), acute phase response Erythrocyte Sedimentation Rate (ESR), and general health status (range 1-100). The index was calculated using the following formula: The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x patient global assessment of disease activity\]. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.
| units on a scale | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|
| Change From Baseline in Disease Activity Score In 28 Joints (DAS28) Score at Week 72 | -0.105 ± 1.2262 | -0.224 ± 1.4961 |
Percentage of participants who achieve score of =1 in TJC and SJC at week 60 and 72 were reported. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28.
| percentage of participants | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|
| TJC <=1, Week 60 | 39.0 | 39.0 |
| SJC <=1, Week 60 | 44.1 | 58.1 |
| TJC <=1, Week 72 | 37.5 | 40.4 |
| SJC <=1, Week 72 | 55.9 | 60.3 |
The DAS28 index was calculated using the following formula: The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x patient global assessment of disease activity\]. Participants who achieve score \<=3.2 at weeks 60 and 72 were reported.
| percentage of participants | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|
| Week 60 | 59.6 | 62.5 |
| Week 72 | 61.0 | 60.3 |
The DAS28 index was calculated using the following formula: The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x patient global assessment of disease activity\]. Participants who achieve DAS28 remission score \<2.6 at weeks 60 and 72 were reported.
| percentage of participants | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|
| Week 60 | 51.5 | 47.1 |
| Week 72 | 50.0 | 51.5 |
The DAS28 index was calculated using the following formula: The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x patient global assessment of disease activity\]. Participants who achieve cDAS28 \>=1.2 score at weeks 60 and 72 were reported.
| percentage of participants | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|
| Week 60 | 9.6 | 16.2 |
| Week 72 | 9.6 | 15.4 |
Clinical Disease Activity Index (CDAI) was an index for measuring disease activity in RA. The index was calculated using the following formula: CDAI: SJC28 + TJC28 + patient global assessment of disease (PGA) 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 'no disease activity' to 'maximum disease activity.' CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity.
| percentage of participants | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|
| Week 60 | 2.9 | 1.5 |
| Week 72 | 1.5 | 3.7 |
Simplified Disease Activity Index (SDAI) was an index for measuring disease activity in RA. The index was calculated using the following formula: CDAI: SJC28 + TJC28 + PGA (10 cm VAS) + PhGA (10 cm VAS + C-Reactive Protein (CRP). VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity. Scores ranged from 0 to 86, with higher scores also indicating increased disease activity.
| percentage of participants | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|
| Week 60 | 2.9 | 0.7 |
| Week 72 | 2.9 | 0.7 |
The HAQ-disability index (DI) evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores and 20 questions. Each category contains multiple questions, which were answered using a 4-point scale from 0 to 3. The overall index score was an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. Improvement was defined as a decrease from Week 24 to Week 60 and 72. Reported is the percentage of participants with an improvement in HAQ-DI score.
| percentage of participants | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|
| Improvement at Week 60 | 27.0 | 39.6 |
| Improvement at Week 72 | 40.5 | 50.0 |
The FACIT-fatigue assessment was a 13-item questionnaire with participants scoring each item on a 5-point scale (not at all; a little bit; somewhat; quite a bit and very much). The total score ranges from 0 to 65 and higher scores indicate more fatigue. Improvement was defined as a decrease from Week 24 to Week 60 and 72. Reported is the percentage of subjects with an improvement in total FACIT score.
| percentage of participants | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|
| Improvement at Week 60 | 54.0 | 50.0 |
| Improvement at Week 72 | 45.2 | 56.3 |
Quality of life questionnaire (SF-12) scores were computed using the scores of 12 questions and ranged from 0 to 100, where a 0 score indicated the lowest level of health measured by the scales and 100 indicated the highest level of health. Improvement was defined as a decrease from Week 24 to Week 60 and 72. Reported is the percentage of subjects with an improvement in SF-12 score.
| percentage of participants | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|
| Improvement at Week 60 | 22.2 | 10.4 |
| Improvement at Week 72 | 23.8 | 15.6 |
| percentage of participants | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|
| Percentage of Participants With Anemia | 1.5 | 0.7 |
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE was any adverse event that can be fatal, life threatening, requires long or prolong hospitalization, results in persistent or significant disability/incapacity, congenital anomaly or significant medical event in the investigator's judgment.
| participants | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|
| AEs | 98 | 98 |
| SAEs | 9 | 3 |
No measurements were reported for this outcome.
The WPAI-SHP questionnaire assesses work productivity and activity impairment. It is a patient-reported assessment regarding hours missed and hours worked at employment and degree to which a specified health problem affected work productivity and regular activities. It consists of 6 questions to assess the impact of a specific health problem on work productivity and on regular daily activities.
| participants | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|
| Week 60 | 33 | 17 |
| Week 72 | 23 | 14 |
The WPAI-SHP questionnaire assesses work productivity and activity impairment. It is a patient-reported assessment regarding hours missed and hours worked at employment and degree to which a specified health problem affected work productivity and regular activities. It consists of 6 questions to assess the impact of a specific health problem on work productivity and on regular daily activities. Reported here are hours actually worked, work hours missed due to rheumatoid arthritis (RA), work hours missed due to other reasons and the change from Week 24 for each of these parameters reported at Week 60 and Week 72.
| hours | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|
| Hours actually worked (HAW), Week 60 (n=33, 17) | 25.0 (0 to 58) | 28.0 (0 to 40) |
| Change from Week 24 in HAW, Week 60 (n=29, 17) | -1.0 (-47 to 40) | 2.0 (-43 to 38) |
| Work hours missed (WHM) to RA, Week 60 (n=33, 17) | 0.0 (0 to 15) | 0.0 (0 to 35) |
| Change from Week 24 in WHM RA, Week 60 (n=30, 16) | 0.0 (-30 to 15) | 0.0 (-7 to 21) |
| WHM other, Week 60 (n=33, 17) | 0.0 (0 to 46) | 0.0 (0 to 35) |
| Change from Week 24 WHM other, Week 60 (n=30, 16) | 0.0 (-56 to 46) | 0.0 (-38 to 35) |
| HAW, Week 72 (n=23, 13) | 30.0 (0 to 48) | 16.0 (0 to 40) |
| Change from Week 24 in HAW, Week 72, (n=20, 12) | 0.0 (-37 to 23) | 2.5 (-30 to 40) |
| WHM to RA, Week 72 (n=23, 13) | 0.0 (0 to 37) | 0.0 (0 to 35) |
| Change from Week 24 in WHM RA, Week 72 (n=21, 11) | 0.0 (-30 to 37) | 0.0 (-7 to 21) |
| WHM other, Week 72 (n=23, 13) | 0.0 (0 to 30) | 0.0 (0 to 8) |
| Change from Week 24 WHM other, Week 72 (n=21, 11) | 0.0 (-56 to 30) | 0.0 (-38 to 2) |
The WPAI-SHP questionnaire assesses work productivity and activity impairment. It is a patient-reported assessment regarding hours missed and hours worked at employment and degree to which a specified health problem affected work productivity and regular activities. It consists of 6 questions to assess the impact of a specific health problem on work productivity and on regular daily activities. Assessments were made using a visual analogue scale ranging from 0 to 10 where 0 = minimum impact and 10 = maximum impact.
| units on a scale | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|
| Productivity (P), Week 60 (n=34, 18) | 2.0 (0 to 8) | 2.0 (0 to 10) |
| Change in P from Week 24 at Week 60 (n=30, 16) | 1.0 (-6 to 8) | 0.0 (-5 to 7) |
| Regular Daily Activities (RDA), Week 60 (n=60, 45) | 3.0 (0 to 9) | 3.0 (0 to 9) |
| Change in RDA from Week 24 at Week 60 (n=59, 44) | 0.0 (-5 to 7) | 0.0 (-6 to 6) |
| Productivity (P), Week 72 (n=24, 12) | 3.0 (0 to 8) | 3.0 (0 to 9) |
| Change in P from Week 24 at Week 72 (n=21, 11) | 0.0 (-3 to 4) | 0.0 (-5 to 7) |
| Regular Daily Activities (RDA), Week 72 (n=42, 31) | 3.0 (0 to 10) | 3.0 (0 to 9) |
| Change in RDA from Week 24 at Week 72 (n=41, 29) | 0.0 (-5 to 4) | -1.0 (-5 to 7) |
Collected over From start of treatment to unscheduled visit (up to Week 72). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Initial Phase | — | 21/427 (4.9%) | 263/427 (61.6%) |
| Methotrexate (MTX) Tapering Group | — | 9/136 (6.6%) | 62/136 (45.6%) |
| Methotrexate (MTX) Maintenance Group | — | 3/136 (2.2%) | 70/136 (51.5%) |
| Event | Initial Phase | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|---|
| DiverticulitisInfections and infestations | 0/427 | 2/136 | 0/136 |
| PneumoniaInfections and infestations | 2/427 | 2/136 | 0/136 |
| Abdominal SepsisInfections and infestations | 0/427 | 1/136 | 0/136 |
| Bursitis InfectiveInfections and infestations | 0/427 | 0/136 | 1/136 |
| Lymph Node TuberculosisInfections and infestations | 0/427 | 0/136 | 1/136 |
| Necrotising FasciitisInfections and infestations | 0/427 | 1/136 | 0/136 |
| Device DislocationGeneral disorders | 0/427 | 1/136 | 0/136 |
| Ankle FractureInjury, poisoning and procedural complications | 0/427 | 1/136 | 0/136 |
| Joint DislocationInjury, poisoning and procedural complications | 0/427 | 1/136 | 0/136 |
| Back PainMusculoskeletal and connective tissue disorders | 0/427 | 1/136 | 0/136 |
| Event | Initial Phase | Methotrexate (MTX) Tapering Group | Methotrexate (MTX) Maintenance Group |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 61/427 | 16/136 | 17/136 |
| DiarrhoeaGastrointestinal disorders | 54/427 | 7/136 | 11/136 |
| Alanine Aminotransferase IncreasedInvestigations | 51/427 | 6/136 | 7/136 |
| Mouth UlcerationGastrointestinal disorders | 48/427 | 5/136 | 9/136 |
| Lower Respiratory Tract InfectionInfections and infestations | 41/427 | 11/136 | 12/136 |
| HeadacheNervous system disorders | 38/427 | 8/136 | 6/136 |
| Upper Respiratory Tract InfectionInfections and infestations | 23/427 | 12/136 | 7/136 |
| RashSkin and subcutaneous tissue disorders | 32/427 | 3/136 | 7/136 |
| CoughRespiratory, thoracic and mediastinal disorders | 29/427 | 8/136 | 6/136 |
| Urinary Tract InfectionInfections and infestations | 19/427 | 9/136 | 6/136 |
| Age, Continuous(years) | Initial Phase |
|---|---|
| Mean | 55.0 ± 12.03 |
| Sex: Female, Male(Participants) | Initial Phase |
|---|---|
| Female | 326 |
| Male | 101 |
The record gives a start of Sep 2012, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methotrexate